Mark T. Fleming, MD, Talks Use of 18F-rhPSMA-7.3 for PET/CT in Recurrent Prostate Cancer
Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.
At the American Urological Association 2022 Annual Meeting, CancerNetwork® spoke with Mark T. Fleming, MD, medical director for the US Oncology Genitourinary Research Committee, Division Chief of Eastern Virginia Medical School Department of Hematology & Oncology, and president of medical staff at Sentara Careplex Hospital, who discussed use of 18F-rhPSMA-7.3 for PET/CT imaging and how use of the agent led to a more frequent baseline post-scan disease upstaging in men with recurrent prostate cancer compared with conventional imaging.
Results of the phase 3 SPOTLIGHT trial (NCT04186845) showed that 18F-rhPSMA-7.3 resulted in a 45% to 47% correct detection rate, defined as the rate at which patients have at least 1 true positive PET finding in comparison with the Standard of Truth histopathology or confirmatory conventional imaging.
Transcript:
It showed that we are able to upstage patients and find diseases that were missed. [Negative findings on conventional imaging give] a false sense of reassurance to patients that they didn’t have a recurrence of the disease. The increase in the upstaging of patients was dramatic. Compared with other PET imaging, this wasn’t a comparator [trial, but rather] an exploratory trial. There are other agents out there, but these are very encouraging data. I had many patients in this trial, and I was very impressed by the data that we saw, [especially] in my own patients.
Reference
Fleming MT. Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: results from the prospective, phase 3, multicenter, SPOTLIGHT study. Presented at: 2022 AUA Annual Meeting; May 13-16, 2022; New Orleans, LA. Abstract PLLBA-02.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
